MediWound Ltd (id:6811 MDWD)
16.48 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 6:36:58 PM)
Exchange closed, opens in 1 day 14 hours
About MediWound Ltd
Market Capitalization 182.40M
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
| Headquarters (address) |
42 Hayarkon Street Yavne 8122745 Israel |
| Phone | 972 7 797 14100 |
| Website | https://www.mediwound.com |
| Employees | 100 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | MDWD |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 8.41 - 24.00 |
| Market Capitalization | 182.40M |
| P/E trailing | -21.97 |
| P/E forward | -7.62 |
| Price/Sale | 9.06 |
| Price/Book | 8.79 |
| Beta | 0.838 |
| EPS | -2.16 |
| EPS Israel (ID:92, base:52) | -0.441 |